Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Explore this paper's citation graph
Summary
It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection is provided that will assist in developing vaccine strategies to control the future trajectory of the pandemic.
- Type
- article
- Published
- 2021-05-17
- Cited by
- 3,638
- References
- 61
- Access
- Open access
- OpenAlex
- https://openalex.org/W3163785571
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:234769053
Keywords
Neutralization, Virology, Antibody, Neutralizing antibody, Medicine
References
- Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children
- Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
- The time course of the immune response to experimental coronavirus infection of man
- Fast Implementation for Normal Mixed Effects Models With Censored Response
- A framework for assessing immunological correlates of protection in vaccine trials.
- Who Invented the Delta Method
- Logistic-normal distributions:Some properties and uses
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
- Confidence intervals for ratios of proportions: implications for selection ratios
- International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE
- Duration of humoral immunity to common viral and vaccine antigens.
- A model for immunological correlates of protection
- Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine.
- Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
- Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model
- Intraseason Waning of Influenza Vaccine Protection: Evidence From the US Influenza Vaccine Effectiveness Network, 2011–2012 Through 2014–2015
- Heterogeneity and longevity of antibody memory to viruses and vaccines
- Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and "Universal" Vaccine Development.
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
Cited by
- Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
- Understanding 'hybrid immunity': comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines.
- An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
- Accuracy of rapid point-of-care antibody test in patients with suspected or confirmed COVID-19
- Decay of Fc-dependent antibody functions after mild to moderate COVID-19
- Personalized-Dose COVID-19 Vaccination in a Wave of Virus Variants of Concern: Trading Individual Efficacy for Societal Benefit
- SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
- SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
- Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
- S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Register Nr. 021-031 – Stand: 07.01.21
- Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
- Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC—COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
- Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation
- SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days
- Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy
- Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
- Standardised, quantitative neutralisation responses to SARS-CoV-2 Variants of Concern by convalescent anti-sera from first wave infections of UK Health Care Workers and Patients
- Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination
- Influence of past infection with SARS-CoV-2 on the response to the BioTech/ Pfizer BNT162b2 mRNA vaccine in health care workers: kinetics and durability of the humoral response
- Six months of COVID vaccines: what 1.7 billion doses have taught scientists
Related papers
- Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01
- An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer
- Heterogeneity in the properties of 7 S and 19S rabbit-neutralizing antibodies to herpes simplex virus.
- Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
- Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
- Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma
- Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
- Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.
- Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum